These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 19464926

  • 21. Sevelamer worsens metabolic acidosis in hemodialysis patients.
    De Santo NG, Frangiosa A, Anastasio P, Marino A, Correale G, Perna A, Di Stazio E, Stellato D, Santoro D, Di Meglio E, Iacono G, Ciacci C, Savica V, Cirillo M.
    J Nephrol; 2006; 19 Suppl 9():S108-14. PubMed ID: 16736432
    [Abstract] [Full Text] [Related]

  • 22. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan.
    Koiwa F, Onoda N, Kato H, Tokumoto A, Okada T, Fukagawa M, Shigematsu T, ROD 21 Clinical Research Group.
    Ther Apher Dial; 2005 Aug; 9(4):340-6. PubMed ID: 16076379
    [Abstract] [Full Text] [Related]

  • 23. Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.
    Ramos R, Moreso F, Borras M, Ponz E, Buades JM, Teixidó J, Morey A, Garcia C, Vera M, Doñate MT, de Arellano MR, Barbosa F, González MT.
    Perit Dial Int; 2007 Aug; 27(6):697-701. PubMed ID: 17984434
    [Abstract] [Full Text] [Related]

  • 24. Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study.
    Bengsch S, Boos KS, Nagel D, Seidel D, Inthorn D.
    Shock; 2005 Jun; 23(6):494-500. PubMed ID: 15897800
    [Abstract] [Full Text] [Related]

  • 25. Endotoxin-binding affinity of sevelamer: a potential novel anti-inflammatory mechanism.
    Sun PP, Perianayagam MC, Jaber BL.
    Kidney Int Suppl; 2009 Dec; (114):S20-5. PubMed ID: 19946323
    [Abstract] [Full Text] [Related]

  • 26. Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.
    Iwasaki Y, Takami H, Tani M, Yamaguchi Y, Goto H, Goto Y, Goto Y, Shigematsu T.
    Ther Apher Dial; 2005 Aug; 9(4):347-51. PubMed ID: 16076380
    [Abstract] [Full Text] [Related]

  • 27. Effect of gastric acid suppression with pantoprazole on the efficacy of sevelamer hydrochloride as a phosphate binder in haemodialysis patients: a pilot study.
    Lai B, Cervelli MJ.
    Nephrology (Carlton); 2012 May; 17(4):402-6. PubMed ID: 22329674
    [Abstract] [Full Text] [Related]

  • 28. [The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].
    Runowski D, Jachimiak B, Cieślak-Puchalska A, Pacanowska B, Zimoń T.
    Pol Merkur Lekarski; 2009 Apr; 26(154):318-21. PubMed ID: 19580197
    [Abstract] [Full Text] [Related]

  • 29. Chronic acid-base perturbations in hemodialysis patients treated with sevelamer hydrochloride: a two-year follow-up study.
    Vlahakos DV, Retsa K, Kalogeropoulou S, Katsoudas S, Bacharaki D, Agroyannis B.
    Artif Organs; 2007 Dec; 31(12):892-5. PubMed ID: 17924988
    [Abstract] [Full Text] [Related]

  • 30. Buffering effects of calcium carbonate as clarified by sevelamer hydrochloride monotherapy.
    Akatsuka T, Mochizuki T, Koike T.
    Ther Apher Dial; 2008 Jun; 12(3):216-25. PubMed ID: 18503699
    [Abstract] [Full Text] [Related]

  • 31. Survival in end stage renal disease: calcium carbonate vs. sevelamer.
    Borzecki AM, Lee A, Wang SW, Brenner L, Kazis LE.
    J Clin Pharm Ther; 2007 Dec; 32(6):617-24. PubMed ID: 18021340
    [Abstract] [Full Text] [Related]

  • 32. [Either calcium carbonate or sevelamer decreases urinary oxalate excretion in chronic renal failure patients].
    Caravaca F, Ruiz AB, Escola JM, Hernández Gallego R, Cerezo I, Fernández N, Barroso S, Martín MV.
    Nefrologia; 2007 Dec; 27(4):466-71. PubMed ID: 17944584
    [Abstract] [Full Text] [Related]

  • 33. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients.
    Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P.
    Am Heart J; 2005 May; 149(5):820-5. PubMed ID: 15894962
    [Abstract] [Full Text] [Related]

  • 34. Reduction of hyperphosphatemia is related with the reduction of C-reactive protein in dialysis patients. Study in sevelamer-resistant dialysis patients treated with chitosan chewing gum as salivary phosphate binder.
    Calò LA, Savica V, Piccoli A, Fusaro M, D'Angelo A, Davis PA.
    Ren Fail; 2011 May; 33(1):11-4. PubMed ID: 21219199
    [Abstract] [Full Text] [Related]

  • 35. Interleukin-6 is a predictor of mortality in stable hemodialysis patients.
    Hasuike Y, Nonoguchi H, Ito K, Naka M, Kitamura R, Nanami M, Tokuyama M, Kida A, Otaki Y, Kuragano T, Nakanishi T.
    Am J Nephrol; 2009 May; 30(4):389-98. PubMed ID: 19690405
    [Abstract] [Full Text] [Related]

  • 36. Switching from calcium carbonate to sevelamer hydrochloride has suppressive effects on the progression of aortic calcification in hemodialysis patients: assessment using plain chest X-ray films.
    Izumi M, Morita S, Nishian Y, Miyamoto T, Kasumoto H, Oue M, Hori K, Kitamura R, Yamamoto S, Nakanishi T.
    Ren Fail; 2008 May; 30(10):952-8. PubMed ID: 19016145
    [Abstract] [Full Text] [Related]

  • 37. Genomic damage and circulating AGE levels in patients undergoing daily versus standard haemodialysis.
    Fragedaki E, Nebel M, Schupp N, Sebekova K, Völkel W, Klassen A, Pischetsrieder M, Frischmann M, Niwa T, Vienken J, Heidland A, Stopper H.
    Nephrol Dial Transplant; 2005 Sep; 20(9):1936-43. PubMed ID: 15919695
    [Abstract] [Full Text] [Related]

  • 38. Sevelamer carbonate reduces inflammation and endotoxemia in an animal model of uremia.
    Hauser AB, Azevedo IR, Gonçalves S, Stinghen A, Aita C, Pecoits-Filho R.
    Blood Purif; 2010 Sep; 30(3):153-8. PubMed ID: 20861617
    [Abstract] [Full Text] [Related]

  • 39. Sevelamer prescriptions after reporting of the Dialysis Clinical Outcomes Revisited (DCOR) trial findings: An analysis of 5,495 patients receiving maintenance dialysis in Ontario, Canada.
    Weir MA, Jain AK, Gomes T, Juurlink DN, Mamdani M, Li L, Garg AX.
    Am J Kidney Dis; 2011 Feb; 57(2):357-9. PubMed ID: 21251552
    [No Abstract] [Full Text] [Related]

  • 40. Anorexia and plasma levels of free tryptophan, branched chain amino acids, and ghrelin in hemodialysis patients.
    Bossola M, Scribano D, Colacicco L, Tavazzi B, Giungi S, Zuppi C, Luciani G, Tazza L.
    J Ren Nutr; 2009 May; 19(3):248-55. PubMed ID: 19243975
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.